NZ721934A - Compositions and methods for treatment of abnormal cell growth - Google Patents

Compositions and methods for treatment of abnormal cell growth

Info

Publication number
NZ721934A
NZ721934A NZ721934A NZ72193415A NZ721934A NZ 721934 A NZ721934 A NZ 721934A NZ 721934 A NZ721934 A NZ 721934A NZ 72193415 A NZ72193415 A NZ 72193415A NZ 721934 A NZ721934 A NZ 721934A
Authority
NZ
New Zealand
Prior art keywords
composition
pharmaceutically acceptable
acceptable salt
weight
pharmaceutical composition
Prior art date
Application number
NZ721934A
Other languages
English (en)
Inventor
Mahesh Padval
Paul Nkansah
Original Assignee
Pfizer
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Verastem Inc filed Critical Pfizer
Priority to NZ760233A priority Critical patent/NZ760233A/en
Publication of NZ721934A publication Critical patent/NZ721934A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
NZ721934A 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth NZ721934A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ760233A NZ760233A (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925467P 2014-01-09 2014-01-09
PCT/US2015/010810 WO2015106096A1 (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
NZ721934A true NZ721934A (en) 2022-04-29

Family

ID=52434976

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ721934A NZ721934A (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth
NZ760233A NZ760233A (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ760233A NZ760233A (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Country Status (15)

Country Link
US (3) US20150190346A1 (https=)
EP (2) EP3091981B1 (https=)
JP (5) JP6647204B2 (https=)
KR (3) KR102444494B1 (https=)
CN (3) CN119868364A (https=)
AU (4) AU2015204597B2 (https=)
BR (1) BR112016016021B1 (https=)
CA (1) CA2936283C (https=)
DK (1) DK3091981T3 (https=)
ES (1) ES2870562T3 (https=)
IL (2) IL246667B (https=)
MX (2) MX384259B (https=)
NZ (2) NZ721934A (https=)
SG (2) SG10201805890QA (https=)
WO (1) WO2015106096A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102942294B1 (ko) * 2018-05-15 2026-03-23 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 소분자 이지에프알 억제제를 포함하는 약학 조성물 및 그의 제조 방법
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
EP4125896B1 (en) * 2020-03-27 2025-05-07 Pfizer Inc. Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
SI3965742T1 (sl) * 2020-04-24 2023-10-30 Dr. Falk Pharma Gmbh Sistemska formulacija piridinonskega derivata za bolezni, povezane s tg2
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
EP1653926A1 (en) * 2003-08-04 2006-05-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
BRPI0810411B8 (pt) 2007-04-18 2021-05-25 Pfizer Prod Inc derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica
MX2011001782A (es) * 2008-08-13 2012-02-08 Vertex Pharma Composicion farmaceutica y su administracion.
WO2011112922A2 (en) * 2010-03-11 2011-09-15 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
WO2012027247A2 (en) * 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
EP2654726A1 (en) * 2011-03-08 2013-10-30 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
EP2572731A1 (en) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions
ES2779975T3 (es) * 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
JP2018519327A (ja) * 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 治療用組成物、組合せ物および使用の方法

Also Published As

Publication number Publication date
CN106102744A (zh) 2016-11-09
AU2020210153A1 (en) 2020-08-13
MX2016009056A (es) 2017-01-23
JP2017502062A (ja) 2017-01-19
CN115708827A (zh) 2023-02-24
AU2015204597B2 (en) 2020-04-30
JP2022001587A (ja) 2022-01-06
IL292054A (en) 2022-06-01
WO2015106096A1 (en) 2015-07-16
BR112016016021A8 (pt) 2018-04-17
AU2020210153B2 (en) 2022-07-21
DK3091981T3 (da) 2021-05-31
ES2870562T3 (es) 2021-10-27
KR20240159639A (ko) 2024-11-05
IL246667A0 (en) 2016-08-31
AU2015204597A1 (en) 2016-07-21
MX384259B (es) 2025-03-14
BR112016016021B1 (pt) 2023-01-10
KR20220130251A (ko) 2022-09-26
EP3091981A1 (en) 2016-11-16
AU2025204843A1 (en) 2025-07-17
US20150190346A1 (en) 2015-07-09
EP3900726A1 (en) 2021-10-27
SG10201805890QA (en) 2018-08-30
CA2936283C (en) 2023-02-28
CN119868364A (zh) 2025-04-25
AU2022256144A1 (en) 2022-11-24
JP2020007355A (ja) 2020-01-16
US20230104303A1 (en) 2023-04-06
EP3091981B1 (en) 2021-03-10
AU2022256144B2 (en) 2025-04-03
JP6647204B2 (ja) 2020-02-14
IL246667B (en) 2022-05-01
KR20160104725A (ko) 2016-09-05
US20200038331A1 (en) 2020-02-06
BR112016016021A2 (pt) 2017-09-19
MX2021008225A (es) 2021-08-11
KR102444494B1 (ko) 2022-09-20
JP2023065568A (ja) 2023-05-12
NZ760233A (en) 2022-04-29
JP2025084892A (ja) 2025-06-03
SG11201605588YA (en) 2016-08-30
CA2936283A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
AU2022256144B2 (en) Compositions and methods for treatment of abnormal cell growth
JP5658679B2 (ja) ベンダムスチンの固体投与剤
CN108367005A (zh) 包含酪氨酸蛋白激酶抑制剂的剂型组合物
KR101977785B1 (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법
CN102711761B (zh) 溶出稳定化制剂
HK40062771A (en) Compositions and methods for treatment of abnormal cell growth
CN115835859A (zh) 包括西他列汀和达格列净的复合制剂以及其制备方法
HK1230956B (en) Compositions and methods for treatment of abnormal cell growth
EP4168011B1 (en) Oral formulations and uses thereof
KR101641319B1 (ko) 안정성이 개선된 에카베트와 라니티딘의 복합 제제
HK1230942A1 (en) Compositions and methods for treatment of abnormal cell growth
CN119365195A (zh) 含有匹米替比的医药组合物
TW202432128A (zh) （Ｒ）－１－（１－丙烯醯基哌啶－３－基）－４－胺基－３－（４－苯氧基苯基）－１Ｈ－咪唑並［４，５－ｃ］吡啶－２（３Ｈ）－酮之藥品調配物
KR20260022394A (ko) 에스트로겐 수용체 분해제의 고형 경구제
CN115837013A (zh) 枸橼酸爱地那非胶囊剂及其制备方法和用途

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 942997, PFIZER INC., 235 EAST 42ND STREET, NEW YORK, NEW YORK 10017, US; 3528888, VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, MA, NEEDHAM 02494, US

Effective date: 20161003

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JAN 2024 BY COMPUTER PACKAGES INC

Effective date: 20221217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JAN 2025 BY COMPUTER PACKAGES INC

Effective date: 20240317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JAN 2026 BY COMPUTER PACKAGES INC

Effective date: 20241217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JAN 2027 BY COMPUTER PACKAGES INC

Effective date: 20251217